Nov 07, 2019 - The company reported third-quarter 2019 operating results and deepened its relationship with Gilead Sciences.
Oct 25, 2019 - Galapagos NV (NASDAQ:GLPG) Q3 2019 Results Conference Call October 25, 2019 08:00 AM ET Company Participants Elizabeth Goodwin - VP, IR Onno van de Stolpe - CEO Bart Filius - COO and CFO Walid Abi-Saa
Oct 25, 2019 - GLPG earnings call for the period ending September 30, 2019.
Oct 25, 2019 - Gilead (GILD) falls short of earnings estimates but marginally beats on sales in the third quarter of 2019.
Oct 09, 2019 - Gilead's (GILD) new drug application for its JAK1 inhibitor filgotinib seeks treatment of rheumatoid arthritis in adult patients across Japan.
Apr 28, 2019 - Galapagos NV (NASDAQ:GLPG) Q1 2019 Results Earnings Conference Call April 26, 2019 08:00 AM ET Company Participants Elizabeth Goodwin - VP of IR & Corporate Communications Onno van de Stolpe - Chi
Apr 26, 2019 - GLPG earnings call for the period ending March 31, 2019.
Apr 08, 2019 - Gilead (GILD) submits sNDA to the FDA for label expansion of Descovy as PrEP to reduce the risk of sexually acquired HIV-1 infection.
Apr 01, 2019 - Shares of Gilead Sciences and Teva Pharmaceutical Industries are bargains right now.
Mar 29, 2019 - Gilead (GILD) and partner Galapagos announce positive results from late-stage studies on investigational drug, filgotinib for the treatment of RA.